Purpose: There is evidence supporting the concept of tumor progression from pulmonary adenocarcinoma in situ (formerly bronchioloalveolar carcinoma, BAC) to adenocarcinoma with varying degrees of invasion. The aim of this study was to investigate the role of transforming growth factor β1 (TGFβ1) in tumor invasiveness in lung adenocarcinoma, and to determine the potential relationships between its expression and immunophenotypes of cell adhesion molecules. Materials and Methods: Tumor samples from adenocarcinoma in situ (n=13), minimally invasive adenocarcinoma (formerly BAC with ≤5 mm invasion, n=2), and lepidic predominant invasive adenocarcinoma (formerly mixed adenocarcinoma showing non-mucinous BAC features with >5 mm invasion, n=25) were examined for the expression of TGFβ1, E-cadherin, N-cadherin, and H-cadherin proteins using immunohistochemistry. Results: Of a total of 40 cases, 25 (63%) were positive for TGFβ1. The frequency of immunoreactivity in patients with adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant invasive adenocarcinoma was 23% (3/13), 50% (1/2), and 84% (21/25), respectively (p=0.001). TGFβ1 correlated with T classification (p=0.006) and stage (p=0.001). Loss of E-cadherin expression was more frequently observed in invasive adenocarcinomas than in adenocarcinomas in situ (p=0.034). E-cadherin expression inversely correlated with T classification (p=0.009). TGFβ1 expression showed a statistically significant correlation with H-cadherin expression (p=0.040), but not with E-cadherin expression (p=0.752). Conclusion: These results suggest that TGFβ1 and E-cadherin may play an important role in invasive progression of lung adenocarcinoma through regulating epithelial-to-mesenchymal transition. (J Lung Cancer 2012;11(1):38 44)
INTRODUCTION
Pulmonary adenocarcinoma in situ (formerly bronchioloalveolar carcinoma, BAC) grows in a lepidic fashion along the alveolar septa. The diagnosis is restricted to noninvasive lesions as defined by the World Health Organization (WHO) (1) . The lepidic growth pattern sometimes seen in varying degrees with invasive adenocarcinomas (2) has led to the hypothesis of tumor progression from in situ carcinoma to invasive adenocarcinoma (3, 4) . Sequential accumulation of genetic aberrations may resultin the development of increasingly invasive tumor phenotypes. It remains unclear which molecular events are responsible for invasive progression of pulmonary adenocarcinoma.
The transforming growth factor β (TGFβ) signaling pathway plays a dual role in epithelial malignancies. TGFβ acts as a tumor suppressor early in tumorigenesis, but when genetic or epigenetic alterations in multiple pathways compromise the tumor suppressor activity later in the process, it then functions as an oncogene to promote tumor progression (5, 6) . Three TGFβ isoforms (TGFβ1, TGFβ2, TGFβ3) are expressed in mammals, and TGFβ1 is the most abundant and universally expressed isoform. The expression of TGFβ1 has been reported in various human malignancies, including lung carcinoma. TGFβ1 expression is associated with angiogenesis and plays a role in tumor progression of non-small cell lung carcinomas (NSCLC) (7) . The acquisition of epithelial-to-mesenchymal transition (EMT) may be induced by TGFβ, especially TGFβ1 (8, 9) . EMT phenotype in cancers has been associated with tumor invasion, metastasis and poor clinical outcome (9) . However, the precise mechanisms that mediate these processes remain poorly defined, especially for lung adenocarcinoma.
In the present study, samples obtained from patients with pulmonary adenocarcinoma demonstrating lepidic pattern with or without invasion were re-categorized according to the new criteria by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (10), and were investigated using immunohistochemistry for the expression of TGFβ1 to determine its role in invasive progression. Cell adhesion molecules, including E-cadherin, N-cadherin, and H-cadherin proteins were also evaluated for possible correlation with TGFβ1.
MATERIALS AND METHODS

1) Study materials
Pathology reports were searched through a computerized database for patients who were diagnosed as having BAC or adenocarcinoma with BAC features after lung resection at our ＞70%), and were interpreted as positive when the scores were ≥2 (12). Cases with ≥2% immunoreactive tumor cells were assigned a positive score for N-cadherin (13).
3) Statistical analysis
Statistical analysis was carried out using the SPSS software package version 13.0 (SPSS Inc., Chicago, IL, USA). Associations between clinicopathologic factors and protein expressions were estimated using Spearman's chi-square test and
Fisher's exact test. All p-values were two-sided. p＜0.05 was considered statistically significant. AIS and MIA were grouped together, the results were the same.
RESULTS
The central area of the LPIA, which showed invasive components, and the peripheral area, which showed lepidic pattern, were examined separately for the immunoreactivities for each and E-cadherin expressions (p=0.752) (Table 4 ). TGFβ1, however, strongly correlated with H-cadherin expression (p=0.040).
DISCUSSION AND CONCLUSION
TGFβs are members of a large superfamily of pleiotropic cytokines, and regulate complex processes including cell proliferation, differentiation, adhesion, cell-cell and cell-matrix interactions, motility, and cell death (14) . TGFβs bind to a heteromeric complex of serine/threonine kinases, the type I and type II receptors (TβRI and TβRII). carcinoma, colorectal carcinoma and NSCLC (7, 11, 20) . An investigation of NSCLC by Hasegawa et al. (7) showed that In conclusion, high expression of the EMT phenotype (high TGFβ1 and low E-cadherin) was more frequently observed in tumors with invasive morphology, suggesting that TGFβ1 overexpression and down-regulation of E-cadherin may provide a favorable environment for tumor cell invasion. Although TGFβ1, E-cadherin, and H-cadherin have been implicated in EMT, the underlying molecular mechanisms need to be elucidated.
